MBX Biosciences MBX 深 沪
交易中 10-06 10:19:06 美东时间
57.45
-1.090
-1.86%
华盛通- 最 高69.50
- 今 开58.75
- 成交量 2.12万股
- 最 低 52.32
- 昨 收 58.54
- 总市值 0
- 52周最高 72.64
- 市盈率 静 --
- 换手率 Infinity.00%
- 52周最低 13.22
- 委 比 -46.15%
- 总股本 --
- 历史最高 72.64
- 量 比 0.57
- 振 幅 29.35%
- 历史最低 4.8069
- 每 手 1
- 风险率 15.53%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多MBX Biosciences Highlights Sustained Calcium Control In Rare Disease
MBX Biosciences reported one-year canvuparatide data showing sustained calcium control and progress toward a Phase 3 trial.
06-12 22:43
Earnings Scheduled For May 14, 2026
Companies Reporting Before The Bell • Urban One (NASDAQ:UONEK) is expected to r...
05-14 19:11
Earnings Scheduled For February 12, 2026
Companies Reporting Before The Bell • Ambev (NYSE:ABEV) is estimated to report ...
02-12 19:11
Earnings Scheduled For December 18, 2025
Companies Reporting Before The Bell • Birkenstock Holding (NYSE:BIRK) is expect...
2025-12-18 19:11
TD Cowen Initiates Coverage On MBX Biosciences with Buy Rating
TD Cowen analyst Tyler Van Buren initiates coverage on MBX Biosciences (NASDAQ:MBX) with a Buy rating.
2025-11-04 20:28
MBX Biosciences Appoints Andreas Moraitis, M.D., as Senior Vice President of Clinical Development
MBX Biosciences appoints Dr. Andreas Moraitis as Senior Vice President of Clinical Development to lead the advancement of canvuparatide for hypoparathyroidism treatment, leveraging his extensive experience in endocrinology and clinical development.
2025-06-23 12:00
MBX Biosciences Announces IND Submission of MBX 4291, its Long-acting GLP1/GIP Receptor Co-agonist Prodrug for the Treatment of Obesity
<p align="center"><em>MBX Biosciences submitted an IND application for MBX 4291, a monthly GLP-1/GIP receptor co-agonist for obesity treatment, with Phase 1 trials expected to begin in Q3 2025.</em>
2025-06-16 12:00
MBX Biosciences to Present at the American Diabetes Association 85th Scientific Sessions
MBX Biosciences announced its participation in the ADA's 85th Scientific Sessions with two posters on MBX 1416, a GLP-1 receptor antagonist, highlighting its safety, efficacy, and potential for treating post-bariatric hypoglycemia. The Phase 1 results suggest once-weekly treatment benefits, with Phase 2 expected later this year.
2025-06-10 12:00
Reported Earlier, MBX Biosciences Prices Initial Public Offering Of 10.20M Common Shares At $16/Share
The gross proceeds to MBX Biosciences from the offering, before deducting the underwriting discounts and commissions and offering expenses, are expected to be $163.2 million. All of the shares are being offered by MBX
2024-09-13 15:27
